Phase 3 SMART trial found clesrovimab was well tolerated in high-risk infants through 2 RSV seasons, with safety comparable to palivizumab.
Anushua Sinha, MD, MPH
Advertisement
Anushua Sinha, MD, MPH, is an infectious diseases physician at Merck.
Articles by Anushua Sinha, MD, MPH
Clesrovimab has been shown to maintain RSV-protection in infants across 2 RSV seasons, while also having positive safety data.
Clinical trial data demonstrate that clesrovimab maintains a safety profile comparable to palivizumab while providing significant protection against RSV-related infections.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FAQ: What does the AAP's updated drowning prevention policy mean for pediatric practice?
2
Collaborative care program increases pediatricians’ confidence in managing pediatric mental health
3
Can you guess the diagnosis of this 19-year-old boy with Down syndrome and progressive loss of communication?
4
Study finds no association between neonatal circumcision and autism diagnosis
5